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Background
Myostatin (MSTN), a TGF-b superfamily member, is a
negative regulator of muscle mass that plays an important
role in metabolism. Mstn KO mice have increased muscle
mass, reduced adipose mass and improved insulin sensitiv-
ity. We have recently shown that MSTN inhibition in
muscle prevents the development of diabetes in a mouse
model of lipodystrophy. Whether inhibition of MSTN in a
type I diabetes model would improve hyperglycemia is
unknown.
Materials and methods
We used streptozotocin (STZ)-treated C57 mice in which
the insulin-producing b-cells were specifically damaged
leading to hyperglycemia. After overt diabetes developed,
the STZ-treated mice were injected with a MSTN inhibi-
tor, a soluble Activin receptor type II B (ACVR2B:Fc).
Blood glucose levels were measured regularly by gluc-
ometer. Pyruvate tolerance and glutamine tolerance tests
were performed and several hormones in the serum were
measured. Real-time PCR was used to compare the expres-
sion level of some genes involved in gluconeogenesis.
Results
The soluble ACVR2B:Fc-treated STZ mice have higher
blood glucose levels compared with untreated STZ mice.
There were no differences in insulin and glucagon levels
between ACVR2B:Fc treated or untreated STZ mice.
However, there were higher levels of the glucocorticoid
corticosterone in soluble ACVR2B:Fc-treated mice. Real-
time PCR data showed that the expression of the PEPCK
gene was increased significantly in ACVR2B:Fc-treated
mice.
Conclusion
Our data suggest that the soluble ACVR2B:Fc treatment
worsens hyperglycemia possibly due to increased gluco-
neogenesis. These data suggest that MSTN inhibition
will not be useful for treating type I diabetes.
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